Ceapro (CRPOF) News Today

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

$0.18

0.00 (0.00%)

(As of 04/19/2024 ET)

Stock Analysis Chart Earnings Headlines Short Interest

Source

Source	Headline
	Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris finanznachrichten.de - March 28 at 10:41 AM
	Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris globenewswire.com - March 28 at 7:55 AM
	Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings globenewswire.com - March 12 at 2:10 PM
	Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company globenewswire.com - February 26 at 7:30 AM
	Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business globenewswire.com - February 23 at 9:00 AM
	Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris globenewswire.com - February 15 at 5:50 PM
	Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases finance.yahoo.com - December 13 at 11:16 AM
	Ceapro GAAP EPS of -C$0.01, revenue of C$2.62M msn.com - November 29 at 5:40 PM
	Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology finance.yahoo.com - November 7 at 11:49 AM
	Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation finance.yahoo.com - July 18 at 9:13 AM
	Ceapro Inc.: Ceapro Announces Results of 2023 Shareholders' Meeting finanznachrichten.de - June 7 at 11:04 AM
	Ceapro Announces Results of 2023 Shareholders’ Meeting finance.yahoo.com - June 7 at 11:04 AM
	Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations finance.yahoo.com - April 27 at 10:28 AM
	Closing Bell: Ceapro Inc flat on Tuesday (CZO) theglobeandmail.com - April 26 at 6:54 PM
	Closing Bell: Ceapro Inc flat on Monday (CZO) theglobeandmail.com - April 25 at 3:08 PM
	Closing Bell: Ceapro Inc down on Thursday (CZO) theglobeandmail.com - April 13 at 9:06 PM
	Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference finance.yahoo.com - March 23 at 9:51 AM
	Ceapro Inc. (CRPOF) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - March 14 at 6:14 PM
	Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society finance.yahoo.com - March 8 at 6:48 PM
	Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company finance.yahoo.com - February 21 at 1:15 PM
	Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event finance.yahoo.com - January 10 at 9:08 AM
	Ceapro receives approval to begin human trial for anti-inflammatory drug msn.com - December 22 at 2:37 PM
	Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets technews.tmcnet.com - December 22 at 9:37 AM
	Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights finance.yahoo.com - November 9 at 12:39 PM
	Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets finance.yahoo.com - November 7 at 10:18 AM
	Ceapro Lone Stock at 52-Week High ca.finance.yahoo.com - August 26 at 12:11 PM
	Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis financialpost.com - August 11 at 9:14 AM
	Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids finance.yahoo.com - August 9 at 9:33 AM
	Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference finance.yahoo.com - May 23 at 9:55 AM
	Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids benzinga.com - May 13 at 9:31 AM
	Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise financialpost.com - March 10 at 9:16 AM
	Ceapro Inc. to Present at the Virtual Investor 2022 Top Picks Conference benzinga.com - January 20 at 9:43 AM
	Ceapro Inc. Announces R&D Funding to Support PGX Technology Project finance.yahoo.com - November 29 at 9:00 AM
	Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights finance.yahoo.com - November 17 at 9:17 AM
	Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels finance.yahoo.com - November 17 at 9:17 AM
	Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG) finance.yahoo.com - November 11 at 10:26 AM
	Ceapro Inc.'s (CVE:CZO) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock? finance.yahoo.com - October 26 at 10:56 AM
	Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights finance.yahoo.com - August 26 at 4:27 PM
	Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan ... apnews.com - August 24 at 3:35 AM
	Global Electric Vehicle Outlook 2021 au.finance.yahoo.com - August 13 at 5:58 PM

Get Ceapro News Delivered to You Automatically

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CRPOF Media Mentions By Week

CRPOF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRPOF
News Sentiment
▼
0.00

0.52
▲
Average
Medical
News Sentiment

CRPOF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRPOF Articles
This Week
▼
0

0
▲
CRPOF Articles
Average Week

Get Ceapro News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (OTCMKTS:CRPOF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ceapro (CRPOF) News Today

CRPOF Media Mentions By Week

CRPOF Media Sentiment

CRPOF News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info